Scp Vitalife Partners (Israel) Sells 12,964 Shares of Recro Pharma Inc (REPH) Stock

Recro Pharma Inc (NASDAQ:REPH) major shareholder Scp Vitalife Partners (Israel) sold 12,964 shares of the company’s stock in a transaction dated Wednesday, January 3rd. The shares were sold at an average price of $8.88, for a total value of $115,120.32. Following the completion of the sale, the insider now owns 734,269 shares in the company, valued at approximately $6,520,308.72. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Scp Vitalife Partners (Israel) also recently made the following trade(s):

  • On Friday, December 28th, Scp Vitalife Partners (Israel) sold 1,980 shares of Recro Pharma stock. The shares were sold at an average price of $9.44, for a total value of $18,691.20.

Shares of Recro Pharma Inc (NASDAQ REPH) opened at $8.69 on Friday. Recro Pharma Inc has a 52-week low of $5.81 and a 52-week high of $10.59. The company has a current ratio of 1.59, a quick ratio of 1.35 and a debt-to-equity ratio of 0.50.

Institutional investors have recently made changes to their positions in the stock. Teachers Advisors LLC bought a new stake in shares of Recro Pharma during the 2nd quarter valued at about $162,000. California State Teachers Retirement System bought a new stake in shares of Recro Pharma during the 2nd quarter valued at about $169,000. JPMorgan Chase & Co. boosted its position in shares of Recro Pharma by 183.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 21,784 shares of the specialty pharmaceutical company’s stock valued at $197,000 after purchasing an additional 14,098 shares in the last quarter. Schwab Charles Investment Management Inc. bought a new stake in shares of Recro Pharma during the 2nd quarter valued at about $215,000. Finally, Wells Fargo & Company MN boosted its position in shares of Recro Pharma by 42.5% during the 3rd quarter. Wells Fargo & Company MN now owns 24,508 shares of the specialty pharmaceutical company’s stock valued at $220,000 after purchasing an additional 7,308 shares in the last quarter. Institutional investors own 61.55% of the company’s stock.

A number of equities research analysts have commented on the company. Zacks Investment Research lowered Recro Pharma from a “buy” rating to a “hold” rating in a research report on Thursday, November 16th. Piper Jaffray Companies reiterated a “buy” rating and issued a $11.00 price target on shares of Recro Pharma in a research report on Friday, October 27th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $11.65.

WARNING: “Scp Vitalife Partners (Israel) Sells 12,964 Shares of Recro Pharma Inc (REPH) Stock” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at https://www.com-unik.info/2018/01/06/scp-vitalife-partners-israel-sells-12964-shares-of-recro-pharma-inc-reph-stock.html.

About Recro Pharma

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Insider Buying and Selling by Quarter for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit